Amgen Inc. $AMGN is China Universal Asset Management Co. Ltd.'s 9th Largest Position

Key Points

• China Universal Asset Management increased its Amgen stake by 10.7% to 71,534 shares (worth $23.41M), making AMGN its 9th largest holding and 1.8% of the firm's portfolio.
• Analyst coverage is mixed with a consensus rating of "Hold" and an average price target of $356.62, while some firms (including Goldman Sachs) have raised price targets and others maintain neutral/hold views.
• Company updates: Amgen completed a Phase 1/2 MTAP‑null cancer combo study, reported a Q4 earnings beat (EPS $5.29 vs. $4.76) with FY2026 guidance of 21.6–23.0 EPS, and declared a quarterly dividend of $2.52 (annualized yield ~2.9%).

China Universal Asset Management Co. Ltd. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,534 shares of the medical research company's stock after purchasing an additional 6,906 shares during the quarter. Amgen makes up 1.8% of China Universal Asset Management Co. Ltd.'s portfolio, making the stock its 9th biggest holding. China Universal Asset Management Co. Ltd.'s holdings in Amgen were worth $23,414,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AMGN. Board of the Pension Protection Fund purchased a new stake in shares of Amgen during the fourth quarter worth about $26,000. Olistico Wealth LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $33,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen during the third quarter worth about $34,000. Saranac Partners Ltd purchased a new stake in shares of Amgen during the third quarter worth about $37,000. Finally, Holos Integrated Wealth LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on AMGN. Weiss Ratings restated a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a report on Thursday, February 5th. Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a report on Thursday, March 19th. Freedom Capital cut Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. Finally, The Goldman Sachs Group raised their price target on Amgen from $403.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $356.62.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Amgen Stock Performance

NASDAQ AMGN opened at $348.62 on Friday. The stock has a market capitalization of $188.14 billion, a PE ratio of 24.50, a P/E/G ratio of 3.62 and a beta of 0.47. The business has a 50 day simple moving average of $361.24 and a two-hundred day simple moving average of $338.80. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company's revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 22.18 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.